Oncology – Urological
RCT: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.
18 Feb, 2022 | 08:47h | UTC
Commentary on Twitter
Adding darolutamide to androgen-deprivation therapy and docetaxel significantly increased overall survival among patients with metastatic, hormone-sensitive prostate cancer. #GU22 https://t.co/GkQZdKgtJs pic.twitter.com/3e5S7tW1Zw
— NEJM (@NEJM) February 17, 2022
Supportive care needs of men with prostate cancer: A systematic review of qualitative studies.
17 Feb, 2022 | 08:34h | UTC
M-A: Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma.
11 Feb, 2022 | 08:15h | UTC
M-A: Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma.
9 Feb, 2022 | 08:39h | UTC
M-A: Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials.
3 Feb, 2022 | 08:31h | UTC
Commentary on Twitter
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysishttps://t.co/cnLe3oxATE@ricautor @spsutkaMD @MRoupret @AndreaNecchi @pcvblack pic.twitter.com/EmeapD8O54
— European Urology (@EUplatinum) January 30, 2022
NCCN Guideline: Kidney Cancer.
2 Feb, 2022 | 08:30h | UTC
Meta-analysis: Androgen deprivation therapy, in addition to radiotherapy, is associated with improved metastasis-free survival in men with localized prostate cancer.
1 Feb, 2022 | 08:24h | UTCAndrogen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)
Perspective | Ultrahypofractionated radiotherapy for localized prostate cancer: how far can we go?
28 Jan, 2022 | 08:09h | UTC
M-A: Late kidney effects of nephron-sparing vs. radical nephrectomy for Wilms Tumor.
27 Jan, 2022 | 09:22h | UTCLate Kidney Effects of Nephron-Sparing vs Radical Nephrectomy for Wilms Tumor: A Systematic Review and Meta-Analysis – The Journal of Urology (link to abstract – $ for full-text)
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
25 Jan, 2022 | 09:28h | UTC
M-A: BRCA1 and BRCA2 pathogenic variants and prostate cancer risk.
25 Jan, 2022 | 09:01h | UTC
Review: Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
25 Jan, 2022 | 08:59h | UTC
Review: Imaging of prostate cancer.
18 Jan, 2022 | 09:20h | UTCImaging of Prostate Cancer – Deutsches Ärzteblatt International
Related:
ASCO Guideline: Optimum Imaging Strategies for Advanced Prostate Cancer
RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management
Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer
Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy
Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.
16 Jan, 2022 | 22:41h | UTCCommentary: Large international evaluation shows AI accurately diagnoses prostate cancer – Karolinska Institutet
Commentary from one of the authors on Twitter (thread – click for more)
Honored to be part of the recently published study in Nature Medicine on the global #AI competition PANDA as a member of the @Google team and an expert panel of 6 US and Canadian Uropathologists. Check out this thread for my 5 top takeaways ?#pathology #PathTwitter
— Dr. Mahul Amin (@DrMahul) January 14, 2022
European Guidelines on non–muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ).
12 Jan, 2022 | 08:32h | UTC
M-A of two randomized trials: Among men with high-risk non-metastatic prostate cancer, adding abiraterone and prednisolone to standard androgen-deprivation therapy was associated with improved 6-year metastasis-free survival (82% vs. 69% in the control group).
8 Jan, 2022 | 22:42h | UTCAbiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol – The Lancet (link to abstract – $ for full-text)
Related Audio: Key messages of the recent report from the STAMPEDE trial platform
Systematic Review: Active surveillance for clinically localized prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy.
8 Jan, 2022 | 22:41h | UTC
Commentary on Twitter
Systematic Review of AS for Clinically Localised PCa to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategyhttps://t.co/U9mA5KqStX@Dr_Willemse @thomas_b_lam pic.twitter.com/j6dgTaqaZs
— European Urology (@EUplatinum) January 3, 2022
M-A: Adjuvant chemotherapy for muscle-invasive bladder cancer.
17 Dec, 2021 | 08:28h | UTC
Commentary on Twitter
Adjuvant Chemotherapy for MIBC: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trialshttps://t.co/EZzsMirWAz
"Cisplatin-based adjuvant chemotherapy is a valid option for improving outcomes for muscle-invasive bladder cancer" pic.twitter.com/dIB1aqqNHn
— European Urology (@EUplatinum) November 26, 2021
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.
8 Dec, 2021 | 09:45h | UTC
Review: Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy.
19 Nov, 2021 | 10:14h | UTCTreatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review – JAMA Oncology (free for a limited period)
Review: Wilms Tumor.
19 Oct, 2021 | 08:44h | UTCWilms tumour – Nature Reviews Disease Primers (free for a limited period)
Infographic: Wilms tumour
Commentary on Twitter
This is a schematic showing the timeline of key advances that established the modern clinical management of children with #Wilms tumour https://t.co/lT9ECVeuiZ pic.twitter.com/7KbMSo7qY3
— Nature Reviews Disease Primers (@DiseasePrimers) October 15, 2021
Review: Recent Advances in the Management of Metastatic Prostate Cancer
1 Oct, 2021 | 09:55h | UTCRecent Advances in the Management of Metastatic Prostate Cancer – JCO Oncology Practice
Clinical Review on the Management of Metastatic Renal Cell Carcinoma.
26 Sep, 2021 | 21:41h | UTCClinical Review on the Management of Metastatic Renal Cell Carcinoma – JCO Oncology Practice
Cohort study: Half of men with low-risk prostate cancer move from surveillance to treatment within a few years.
27 Aug, 2021 | 08:26h | UTC
RCT: New blood test could improve prostate cancer screening.
17 Aug, 2021 | 08:48h | UTCProstate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
News release: New blood test improves prostate cancer screening – Karolinska Institutet
Related:
RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
Commentary on Twitter
Online first: #Prostatecancer #screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial #pcsm https://t.co/bijoJk8RbK pic.twitter.com/ENWEjqG3Kr
— The Lancet Oncology (@TheLancetOncol) August 13, 2021